Study findings published in the International Journal of Infectious Diseases suggest nafamostat, a drug used to treat acute pancreatitis and prevent blood clotting for patients receiving blood dialysis, was found to be effective against COVID-19, reported The Korea Bizwire.
The paper explained that an experiment on three severe coronavirus patients over 65 years of age requiring oxygen treatment revealed that nafamostat was effective against COVID-19 and related inflammation.
Prior to the nafamostat clinical trials, they were treated with the anti-HIV drug Kaletra and the anti-malarial chloroquine.
The medical team gave the COVID-19 patients a dose of nafamostat 200 mg every day, after which patients were able to breathe on their own, with inflammation subsiding.
SK Chemicals Co., an affiliate of South Korean conglomerate SK Group, currently sells nafamostat, which was developed by Torii Pharmaceutical, under the brand name Futan.
Meanwhile, Chong Kun Dang Pharmaceutical is currently discussing plans to request emergency use of napabeltan, that company's generic version of nafamostat.
To read more NewsPoints articles, click here.